Bioptix Inc news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

BIOP 3.71 -0.01 (-0.27%)
price chart
Bioptix Announces Executive Leadership Change
CASTLE ROCK, Colo., April 10, 2017 /PRNewswire/ -- Bioptix, Inc. (Nasdaq: BIOP) ("Bioptix" or the "Company"), announced that its board of directors has appointed Michael M. Beeghley as chief executive officer effective as of April 6, 2017.
Bioptix, Inc (BIOP) Names Michael M. Beeghley as CEO  StreetInsider.com
Bioptix Reports Board of Director Changes
BOULDER, Colo., Jan. 6, 2017 /PRNewswire/ -- Bioptix, Inc. (Nasdaq: BIOP), (the "Company"), announced that Gail Schoettler, Susan Evans and David Welch have resigned from the Company's Board of Directors.
3.96
Bioptix Inc. BiOptix, Inc. is a vitro diagnostic company. The company focuses on the commercializing of its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children adolescent and young adult ...
BRIEF-Bioptix Inc files for mixed shelf offering of up to $20 million - SEC filing
WASHINGTON, March 24 After failing to repeal Obamacare, Republicans in the U.S. Congress quickly pivoted on Friday to President Donald Trump's next priority: overhauling the federal tax code, but their plan has already split the business community.
Bioptix Announces Streamlining of Workforce
20, 2017 /PRNewswire/ -- Bioptix, Inc. (Nasdaq: BIOP) ("Bioptix" or the "Company"), announced that on January 14, 2017 the Board of Directors of the Company adopted a plan under which the Company will terminate certain employees associated with the ...
Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to ...
BOULDER, Colo., Dec. 8, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced that following the approval from shareholders at the 2016 Annual Meeting of Shareholders of the proposal to change the Company's name, the Company's name has ...
Venaxis (APPY) Changes Name to Bioptix; Will Trade Under Ticker 'BIOP'  StreetInsider.com
Form 8-K Bioptix, Inc. For: Apr 10
On April 10, 2017, Bioptix, Inc. (the "Company") received a notice of deficiency from The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with Nasdaq's audit committee requirements as set forth in Nasdaq Listing Rule 5605.
Venaxis Announces Acquisition of BiOptix
13, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced today that it has acquired BiOptix Diagnostics, Inc., ("BiOptix") a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance ...
Honig Is Buying Again: This Time, Bioptix Inc. (NASDAQ:BIOP)
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bioptix Inc. (NASDAQ:BIOP) reported that Honig Barry C. has picked up 504,000 of common stock as of 2017-01-05.
Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Departure of Directors or Certain ...
Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.